INDEX

SESSION 1 ..... **13**
INTEGRATING DRUG UTILIZATION STUDIES IN A WIDER EUROPE 14
POSSIBILITIES FOR INFORMATION EXCHANGE ON NATIONAL REGISTERS ON DRUG USE DATA IN EUROPE 16
MEASURING THE EFFECT OF INTERVENTIONS TO PROMOTE RATIONAL PRESCRIBING 17
LINKING MICRO- AND MACRO- UTILIZATION DATA 18

SESSION 2 ..... **21**
ATC/DDD A GLOBAL STANDARD FOR DRUG CLASSIFICATION AND UTILIZATION RESEARCH 22
WHO ESSENTIAL DRUGS AND MEDICINES POLICY: THE ROLE OF DRUG UTILIZATION 23
AVAILABILITY OF DRUG UTILISATION DATA IN DEVELOPING COUNTRIES 24
INTERNATIONAL COMPARISONS OF ANTIHYPERTENSIVE DRUG USE 25
SUMMING UP: TOWARDS A GLOBAL DRUG UTILIZATION NETWORK 26

SESSION 2B **27**
OTITIS MEDIA: DIFFERENT PATTERNS OF PRESCRIPTION IN BULGARIA, RUSSIA, SLOVAKIA AND SPAIN 28
PREVALENCE OF ANTIBIOTICS AMONG RUSSIAN NON-MEDICAL POPULATION - RESULT OF PROSPECTIVE PHARMACOEPIDEMIOLOGICAL STUDY 29
PROMOTION OF RATIONAL ANTIBIOTIC USE IN FLEMISCH GENERAL PRACTICE: IMPLEMENTATION OF A GUIDELINE FOR ACUTE COUGH 30
PATTERNS OF DRUG PRESCRIBING IN ADULTS WITH ACUTE OTITIS MEDIA AN ACUTE SINUSITIS (AS) 32
WHAT DO RUSSIAN GPS ACTUALLY KNOW ABOUT THE ETIOLOGY AND TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP)? 33
ANTIBIOTIC USE IN HOSPITAL CARE – A MODEL FOR QUALITY ASSESSMENT 35
PARACETAMOL (ACETAMINOPHEN) AND ANTIBIOTICS, THE FREQUENCY OF USE AMONG PRE-SCHOOL CHILDREN 36

SESSION 3 ..... **39**
EUROPEAN SURVEILLANCE OF ANTIBIOTIC CONSUMPTION (ESAC) 40
DRUG UTILIZATION OF ANTIBACTERIALS – A COMPARISON BETWEEN DIFFERENT EUROPEAN COUNTRIES 42
METHODOLOGICAL PROBLEMS IN COLLECTING COMPARABLE ANTIBACTERIAL UTILIZATION DATA 43
RELATIONSHIP BETWEEN ASTHMA CONTROL AND COTHERAPY FOR CONCOMITANT DISEASES 44
ANTIBACTERIAL DRUG USE IN CHILDREN WITH ACUTE RESPIRATORY INFECTIONS - 3 YEAR PHARMACOEPIDEMIOLOGICAL STUDY 45
EVALUATION OF INDIVIDUAL EXPOSURE TO THE ANTIMICROBIALS IN THE HOSPITAL SETTING – AN IMPORTANT TOOL FOR THE INTERPRETING RESULTS OF LOCAL ANTIMICROBIAL RESISTANCE SURVEILLANCE 47
MINIMAL DATASET FOR THE EVALUATION OF GUIDELINES ON ANTIBIOTICS (EGA-STUDY) 49

SESSION 3B **51**
USE AND COST OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS: DIFFERENCES BETWEEN ITALY AND GERMANY 52
ANTI-ASTHMATIC DRUG UTILIZATION AND ASTHMA MORTALITY* 53
ECOTOXICOLOGICAL IMPACT OF DRUGS: THE NEED FOR DRUG UTILIZATION MONITORING 54
IMPACT OF AGE AND GENDER ON THE UTILIZATION OF REIMBURSED AMBULATORY PHARMACEUTICALS IN BELGIUM: HISTORICAL REVIEW 1986 - 1999 55
USING THE GENERAL PRACTICE RESEARCH DATABASE (GPRD) FOR COHORT STUDIES IN PHARMACOEPIDEMIOLOGY: PROBLEMS IN DEFINING THE DENOMINATOR POPULATION 56
INFLUENCE OF THE USED DETERMINATION METHOD ON THE ADHERENCE TO ANTIRETROVIRAL THERAPY ESTIMATION 57

SESSION 4 ..... **59**
INTRODUCTION OF SESSION 4 60
THE EXPERIENCE IN DEVELOPING PHARMACOEPIDEMIOLOGICAL RESEARCH IN THE CZECH REPUBLIC 61
DIFFICULTIES OF DRUG UTILIZATION RESEARCH IN HUNGARY 64
UTILIZATION OF ANTIASTHMATICS AND ACUTE ASTHMA MORTALITY IN THE CZECH REPUBLIC IN 1970-1997 65

PROTON PUMP INHIBITORS AS THE MOST EFFECTIVE INHIBITORS OF GASTRIC SECRETION AND PHARMACO-ECONOMICAL ASPECTS OF THE TREATMENT OF GASTRODUODENAL ULCER DISEASES 66

THE DIFFERENCES BETWEEN PRESCRIBED DAILY DOSES AND DEFINED DAILY DOSES OF ANTIEPILEPTIC 67

ROUTINE HYPERTENSION MANAGEMENT IN BELARUS: QUALITY OF LIFE-, GENDER- AND LIFE-STYLE IMPACT ON DRUG CHOICE AND COMPLIANCE 68

PHARMACOEPIDEMIOLOGICAL STUDY OF BRONCHODILATORS AND ANTI-INFLAMMATORY ANTI-ASTHMA AGENTS IN PEDIATRIC OUT-PATIENT CLINICS OF THE CITY OF KAZAN 69

WORKSHOP I. 71

IMPROVING DRUG PRESCRIBING BY USE OF QUALITY INDICATORS AND FEED BACK 72

SESSION 5 73

INTRODUCTION OF SESSION 5 74

DRUG RELATED MORBIDITY & MORTALITY AND THE INSTITUTE OF MEDICINE (IOM) REPORTS 75

ATTITUDES OF GPS AND SPECIALISTS REGARDING THERAPEUTIC GUIDELINES FOR TRANSMURAL CARE 76

A BIBLIOMETRIC STUDY OF DRUG UTILIZATION RESEARCH IN THE ABSTRACT BOOKS OF THE INTERNATIONAL CONFERENCE OF PHARMACOEPIDEMIOLOGY : 1997-1999 77

GASTROINTESTINAL DRUG USE IN PATIENTS WITH DIABETES IN PRIMARY CARE 79

BENEFITS AND RISKS OF ANTIDEPRESSANTS IN HOSPITAL USE 80

DRUG UTILIZATION RESEARCH AND MONITORING IN DENMARK 81

SESSION 5B 83

FOCUS GROUP DISCUSSIONS - A TOOL FOR EXPLORING UNANTICIPATED ISSUES 84

COUNSELLING PATIENTS WITH PAIN AS A PREREQUISITE TO IMPLEMENTING PHARMACEUTICAL CARE: RESULTS OF A DATABASED QUALITY CIRCLE OF PHARMACISTS IN SAXONY 85

A SET OF INDICATORS TO ASSESS THE SUCCESS OF AN INTERVENTION TO IMPROVE THE PRESCRIBING QUALITY OF LIPID LOWERING DRUGS 86

DISEASE SEVERITY AND ADHERENCE TO HEART FAILURE GUIDELINES IN GENERAL PRACTICE 87

FROM DRUG PRESCRIPTION TO PRESCRIBING REPORTS 88
PREVALENCE OF UNDERDOSING IN AMBULATORY PHARMACOTHERAPY 89
APPLYING QUALITY INDICATORS ON PRESCRIPTION DATA FOR THE ROUTINE EVALUATION OF DRUG USE APPROPRIATENESS 90
DRUG PRESCRIPTION IN TWO DIFFERENT MODELS OF PRIMARY CARE CENTERS 91

SESSION 6 93
COLLECTING DATA ABOUT MEDICINES IN THE EUROPEAN COUNTRIES: RESULTS FROM THE EURO-MEDICINES PROJECT 94
CO-OPERATION BETWEEN DRUG INFORMATION CENTRES (DICS) AND DRUG UTILIZATION RESEARCH GROUPS (DURGS) ON THE NATIONAL LEVEL 95
INTERNET DRUG DATABASE AND STATISTICAL ANALYSES USING OF DRUGS 96
PATIENT INFORMATION LEAFLETS APPROPRIATE DRUG INFORMATION OR A SOURCE OF CONFUSION? 97
NORDIC COMPARISON OF THE USE OF ATC AND DDDS 98
JANUS - A RELIABLE TIME SAVING TOOL IN DRUG PRESCRIBING. 99
COMPASS- A GUIDE FOR GENERAL PRACTITIONERS ON THEIR PRESCRIBING 100

WORKSHOP II. 101
THE USERS' PERSPECTIVE ON MEDICINES - FINDING NEW AREAS 102

POSTERS 105

ATC/DDD
A1. MEDICINES FOR CHILDREN - COMPOUNDING IN NORWEGIAN HOSPITAL PHARMACIES 106
A2. DRUG UTILIZATION ON ANTIDIABETIC DRUGS IN NORWAY 108
A3. MARKED DIFFERENCES IN COSTS FOR NSAIDS BETWEEN CROATIA AND SWEDEN 109
A4. DRUG CONSUMPTION MONITORING IN THE UNIVERSITY HOSPITAL CENTRE ZAGREB 110

Antibiotics Utilization
B1. ANTIBIOTIC CONSUMPTION IN A TERTIARY HOSPITAL IN ISRAEL 111

B2. ANTIMICROBIAL CONSUMPTION IN POLYVALENT INTENSIVE CARE UNIT 112
B3. ANTIBIOTIC CONSUMPTION CHANGES IN THE FACULTY HOSPITAL IN OLOMOUC DURING 1997-1999 113
B4. CEPHALOSPORIN USE: DIFFERENCES BETWEEN ENGLAND AND ITALY 114
B5. DIFFERENT USE OF ANTIBIOTICS IN EUROPE: THE ROLE OF CULTURAL FACTORS 115
B6. THERAPY OF ACUTE TONSILLITIS IN THE HODONÍN REGION 116
B7. ANTIBIOTIC POLICY AND ITS ROLE IN PREVENTION OF NOSOCOMIAL INFECTIONS 117
B8. BACTERIAL RESISTANCE AND THE USE OF ANTIBIOTICS IN SURGICAL AND MEDICAL DEPARTMENTS 118
B9. THE CONSUMPTION OF ANTIBIOTICS AND RESISTANCE OF BACTERIAL ISOLATES IN THE INTENSIVE CARE UNITS AT THE UNIVERSITY TEACHING HOSPITAL IN HRADEC KRÁLOVÉ, CZECH REPUBLIC 119
B10. CONSUMPTION TRENDS OF ANTIMICROBIAL DRUGS AND RECENT CHANGES IN THE MICROBIAL RESISTANCE PATTERN IN THE CZECH REPUBLIC 121
B11. UTILIZATION OF ANTIBIOTICS IN BELGIUM 122
B12. EVOLUTION OF TUBERCULOSIS TREATMENT IN SPAIN 1993-1998 123

DUR in Central and Eastern European Countries

C1. SURVEY OF THE CENTRALIZED DRUG PURCHASING IN THE REPUBLIC OF ARMENIA 124
C2. ANALYSIS OF DRUG CONSUMPTION IN FOUR CENTRAL EUROPEAN COUNTRIES 125
C3. INAPPROPRIATE MEDICATION USE IN COMMUNITY-RESIDING ELDERLY LIVING IN ISFAHAN – BACKGROUND, METHODOLOGY AND CHALLENGES 127
C4. COMPARATIVE ANALYSIS OF THE REGISTRED PSYCHOTROPIC DRUGS BETWEEN LIBYA AND BULGARIA 129
C5. TRENDS IN CONSUMPTION OF INSULIN AND PERORAL ANTIDIABETIC DRUGS IN CZECH REPUBLIC 1997-2000 130
C6. THE PHARMACOTHERAPY IN THE TREATMENT OF ISCHAEMIC HEART DISEASE IN HOSPITAL CONDITIONS 131
C7. DRUG UTILIZATION OF »ANTI-ASTHMA« DRUGS IN THE REGIONAL PEDIATRIC POPULATION 132

C8. PRESCRIBING PATTERNS ANALYSIS – CROSS COUNTRY VARIATIONS IN BULGARIA, ROMANIA, MACEDONIA AND BOSNIJA HERZEGOVINA 133

C9. ANALYSIS OF CONSUMPTION AND COSTS OF PRESCRIPTION DRUGS USED ON CORONARY UNITS 134

C10. CARDIOVASCULAR DISEASES – PHARMACOTHERAPY 135

C11. RECENT TRENDS OF CARDIOVASCULAR DRUGS CONSUMPTION IN THE CZECH REPUBLIC 136

C12. REAL DRUGS PRESCRIPTION PRACTICE IN THE RUSSIAN LARGE SPECIALIZED OUTPATIENT CLINIC: THE FREQUENCY OF POLYPHARMACY AND CONFORMITY TO THE NATIONAL LIST OF ESSENTIAL DRUGS 137

C13. UTILIZATION OF FREE AND PRIVILEGED PRESCRIBED DRUGS IN THE BIG CITY ON THE SOUTHWEST OF RUSSIA: STRUCTURE OF THE CHARGES DEPENDING ON DEFINED GROUPS OF THE PATIENTS 138

C14. COMPARISON OF DRUG UTILIZATION IN TREATING ACUTE MYOCARDIAL INFARCTION IN TWO HOSPITALS IN YUGOSLAVIA 139

C15. CONSUMPTION OF PSYCHOTROPIC DRUGS IN MILITARY MEDICAL ACADEMY-BELGRADE, DURING THE TEN YEARS PERIOD (1990-2000) 140

C16. TRENDS IN CONSUMPTION OF CALCIUM CHANNEL BLOCKERS IN CZECH REPUBLIC 1992-1999 AND COMPARISON WITH SELECTED COUNTRIES 141

C17. CONSUMPTION OF HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE IN HUNGARY (1990-1999) 142

C18. THE CONSUMPTION OF DRUGS FOR THE MANAGEMENT OF PEPTIC ULCER DISEASE IN THE REGION OF HRADEC KRÁLOVÉ, CZECH REPUBLIC 143

State of the Art of Drug

D1. ADVERSE DRUG REACTION MONITORING - ASSESSMENT OF LIPID LOWERING AGENTS ASSOCIATED REACTIONS IN JENA 145

D2. USE OF ANTIDIABETIC DRUGS IN SPAIN DURING THE PERIOD 1989-1998 146

D3. STUDY OF DRUGS PRESCRIBED TO THE ECONOMICALLY WEAK PATIENTS (DESTITUTE) 147

D4. PREVALENCE OF SELF-MEDICATION IN RURAL AREAS OF PORTUGAL – A PILOT STUDY 148

D5. EVALUATION OF PRESCRIPTION AND PATIENT ATTITUDES IN ANTIHYPERTENSIVE DRUG USE AND THE ROLE OF THE PHARMACISTS IN 13 URBAN AREAS 149

D6. CHILDURG: THE EURODURG WORKING GROUP FOR DRUG USE IN CHILDREN 150

D7. DRUG USE IN CHILDREN IN TENERIFE (SPAIN): A COMPARISON 15 YEARS LATER 151

D8. A PILOT STUDY OF A COMMUNITY APPROACH TO THE CONTROL OF HEAD LICE INFESTATION IN 3 INNER CITY PRIMARY SCHOOLS IN BELGIUM 152

D9. DEEP VENOUS THROMBOSIS OF LOW EXTREMITIES: PHARMACOECONOMIC ASPECTS OF THE THERAPY 153

D10. RELEVANCE OF DRUG UTILIZATION DATA IN PHARMACOVIGILANCE 154

D11. PHARMACOEPIDEMIOLOGICAL STUDY OF NEUROLEPTIC--INDUCED EXTRAPYRAMIDAL DISORDERS AT THE REPUBLICAN PSYCHIATRIC HOSPITAL OF THE REPUBLIC OF TATARSTAN 155

D12. A STUDY OF URINARY CULTURE&ANTIBIOGRAM IN IRANIAN CHILDERN WITH URINARY TRACT INFECTION 157

D13. THE INFLUENCE OF ENALAPRIL ON LEFT VENTRICULAR HYPERTROPHY AND QT DISPERSION IN PATIENTS WITH ESSENTIAL HYPERTENSION 158

D14. PATIENT INFORMATION LEAFLET READABILITY TEST 159

D15. MEDICAL-ECONOMICAL VIEW ON PHARMACOTHERAPY OF PEPTIC DISEASES IN CONNECTION WITH HELICOBACTER PYLORI INFECTION 160

D16. THE EFFECT OF ESTROGEN ON GRAFT REJECTION EVENTS 161

D17. DRUG DATA PROCESSING IN THE JOINT ANALYSIS OF THE MONICA OPTIONAL STUDY ON DRUGS 162

Drug Information and Drug Utilization Research

E1. DRUG POLICY – NEW RULES OF PROCEDURE OF THE COMMITTEE OF MINISTRY OF HEALTH FOR DRUG CATEGORISATION 164

E2. ELICITING STAKEHOLDER PREFERENCES IN THE DEVELOPMENT OF A TOOL FOR THE SUPPORT OF COMPUTERISED REPEAT PRESCRIBING MANAGEMENT IN UK GENERAL PRACTICE 165

E3. ANTIPSYCHOTICS AVAILABLE IN THE EUROPEAN UNION 166

E4. THE KNOWLEDGE OF CARDIOVASKULAR DRUGS INTERACTIONS IN EVERYDAY MEDICAL PRACTICE 168

E5. PHARMACOTHERAPEUTICAL INFORMATION 169

E6. ESTABLISHING THERAPY TRADITIONS FOR CARDIOVASCULAR DRUGS 170

E7. THE CONCEPT OF THE OPTIMIZED HOSPITAL FORMULARY 171

E8. FINNISH DATABASES ON DRUG UTILIZATION 172
E9. THE SWEDISH »BIBLE« ON DRUG UTILIZATION 173
E10. TRENDS IN THE USE OF ANTIHYPERTENSIVES IN SPAIN (1995-1999) 174

SPEAKEARS' ADDRESSES 175

LIST OF AUTHORS 183